Literature DB >> 16219538

KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.

Garnet Suck1, Donald R Branch, Mark J Smyth, Richard G Miller, Joanna Vergidis, Soad Fahim, Armand Keating.   

Abstract

OBJECTIVE: To compare the cytotoxicity of KHYG-1 with other natural killer (NK)/NK T-cell lines and identify molecules that may be associated with enhanced cytotoxicity, thereby eventually leading to improved NK cell-mediated cancer immunotherapy.
MATERIALS AND METHODS: NK/NK T-cell lines KHYG-1, NK-92, YT, and SNT-8 were compared with a novel flow cytometric cytotoxicity assay under different culture conditions. Transcription, expression, and phosphorylation studies were performed using polymerase chain reaction sequence-specific primers, reverse transcription polymerase chain reaction, immunoblotting, and flow cytometry.
RESULTS: KHYG-1 is a highly cytotoxic cell line, exceeding the cytolytic capacity of the other cell lines against K562. KHYG-1 is also highly cytotoxic against the leukemia cell lines EM2, EM3, and HL60. The novel activation receptor NKp44 and its adaptor, DAP12, NKG2D, and constitutively phosphorylated ERK2 may be associated with the enhanced cytotoxicity of KHYG-1. This cell line most likely mediates cytolysis by granzyme M (but not granzymes A and B) together with perforin, which is constitutively fully cleaved to the 60-kD form, in contrast to the other cell lines.
CONCLUSION: KHYG-1 is a valuable model for the study of enhanced cytotoxicity by NK cells. In addition to the activation of NKp44, KHYG-1 may induce apoptosis of tumor cells by the newly described granzyme M/perforin pathway. Targeted modifications of effector molecules demonstrated in this model could generate NK cells with even greater killing ability that may be particularly attractive for clinical application. Moreover, our demonstration of greater cytotoxicity of KHYG-1 versus NK-92 cells, already in clinical trials, suggests a direct therapeutic role for KHYG-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219538     DOI: 10.1016/j.exphem.2005.06.024

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  31 in total

1.  Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

Authors:  Brenna E Swift; Brent A Williams; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Sowmya Viswanathan; Joaquin Martinez-Lopez; Armand Keating
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 2.  Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Authors:  Huang Zhu; Yi-Shin Lai; Ye Li; Robert H Blum; Dan S Kaufman
Journal:  Stem Cells       Date:  2018-01-03       Impact factor: 6.277

3.  The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Authors:  Subhashis Sarkar; Sachin K S Chauhan; John Daly; Alessandro Natoni; Heather Fairfield; Robert Henderson; Emma Nolan; Dawn Swan; Jinsong Hu; Michaela R Reagan; Michael O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

4.  Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Authors:  Alexandra C Vrazo; Adrianne E Hontz; Sarah K Figueira; Braeden L Butler; Julie M Ferrell; Brock F Binkowski; Jinzhu Li; Kimberly A Risma
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

Review 5.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

6.  Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor.

Authors:  Tae-Jin Kim; Nayoung Kim; Eun-Ok Kim; Jong-Rip Choi; Jeffrey A Bluestone; Kyung-Mi Lee
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

7.  Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells.

Authors:  Deqing Hu; Shengwu Liu; Lei Shi; Chong Li; Lianfeng Wu; Zusen Fan
Journal:  J Biol Chem       Date:  2010-04-20       Impact factor: 5.157

8.  FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade.

Authors:  S Wang; P Xia; L Shi; Z Fan
Journal:  Cell Death Differ       Date:  2011-10-07       Impact factor: 15.828

9.  VASP Regulates NK Cell Lytic Granule Convergence.

Authors:  Katelynn M Wilton; Daniel D Billadeau
Journal:  J Immunol       Date:  2018-10-03       Impact factor: 5.422

Review 10.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.